Literature DB >> 12655296

Apo2L/TRAIL and its death and decoy receptors.

H N LeBlanc1, A Ashkenazi.   

Abstract

Apo2 ligand or tumour necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is one of the several members of the tumour necrosis factor (TNF) gene superfamily that induce apoptosis through engagement of death receptors (DRs). Apo2L/TRAIL interacts with an unusually complex receptor system of two DRs and three decoys. This protein has garnered intense interest as a potential candidate for cancer therapy because as a trimer it selectively induces apoptosis in many transformed cells but not in normal cells. While much of the early characterisation of Apo2L/TRAIL and its receptors relied on overexpression studies, recent work using untransfected cells has clarified how endogenous proteins transmit apoptotic signals from this ligand. In this review, we focus on the apoptotic signalling pathways stimulated by Apo2L/TRAIL and summarise what is known about its physiological role.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655296     DOI: 10.1038/sj.cdd.4401187

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  241 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  Protein delivery using engineered virus-like particles.

Authors:  Stanislaw J Kaczmarczyk; Kalavathy Sitaraman; Howard A Young; Stephen H Hughes; Deb K Chatterjee
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

4.  Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis.

Authors:  Guang-Chao Liu; Jun Zhang; Shi-Gui Liu; Rong Gao; Zhang-Fu Long; Ke Tao; Yuan-Fang Ma
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 5.  Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

Authors:  Jürgen Sonnemann; Jennifer Gänge; K Saravana Kumar; Cornelia Müller; Peter Bader; James F Beck
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

6.  Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.

Authors:  Hang Zhou; Yunchao Wang; Kuo Bi; Haiyu Qi; Shuju Song; Mingzhu Zhou; Letian Chen; Guochun Wang; Ting Duan
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

7.  CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis.

Authors:  Zhongyu Liu; Xin Xu; Hui-Chen Hsu; Albert Tousson; Ping-Ar Yang; Qi Wu; Cunren Liu; Shaohua Yu; Huang-Ge Zhang; John D Mountz
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

8.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

9.  Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways.

Authors:  Stéphanie Solier; Olivier Sordet; Kurt W Kohn; Yves Pommier
Journal:  Mol Cell Biol       Date:  2008-10-27       Impact factor: 4.272

Review 10.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.